CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-28 | CAREY STEPHEN P. SVP & CFO | Shares withheld for taxes | −2,773 | $73.90 | $205K | 189,543 |
| 2026-02-28 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Shares withheld for taxes | −628 | $73.90 | $46K | 43,502 |
| 2026-02-26 | Davis Krista SVP, CHIEF HR OFFICER | Grant or award | +10,810 | $77.15 | $834K | 60,073 |
| 2026-02-26 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Grant or award | +13,895 | $77.15 | $1.1M | 81,445 |
| 2026-02-26 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Grant or award | +11,116 | $77.15 | $858K | 77,137 |
| 2026-02-26 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Grant or award | +11,116 | $77.15 | $858K | 101,056 |
| 2026-02-26 | Mutz Christopher HEAD OF RARE DISEASE | Grant or award | +21,306 | $77.15 | $1.6M | 106,146 |
| 2026-02-26 | Gutwerg Ori SVP, GENERICS | Grant or award | +12,969 | $77.15 | $1.0M | 89,063 |
| 2026-02-26 | Lalwani Nikhil PRESIDENT & CEO | Grant or award | +75,592 | $77.15 | $5.8M | 434,166 |
| 2026-02-26 | CAREY STEPHEN P. SVP & CFO | Grant or award | +22,233 | $77.15 | $1.7M | 192,316 |
| 2026-02-26 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Grant or award | +6,021 | $77.15 | $465K | 44,130 |
| 2026-02-20 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 | −1,730 | $77.99 | $135K | 49,263 |
| 2026-02-20 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 | −5,323 | $78.02 | $415K | 84,840 |
| 2026-02-19 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 | −2,084 | $77.53 | $162K | 50,993 |
| 2026-02-14 | Davis Krista SVP, CHIEF HR OFFICER | Shares withheld for taxes | −1,290 | $77.36 | $100K | 53,077 |
| 2026-02-14 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Shares withheld for taxes 10b5-1 | −1,779 | $77.36 | $138K | 67,550 |
| 2026-02-14 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Shares withheld for taxes | −1,717 | $77.36 | $133K | 66,021 |
| 2026-02-14 | Mutz Christopher HEAD OF RARE DISEASE | Shares withheld for taxes 10b5-1 | −2,403 | $77.36 | $186K | 90,163 |
| 2026-02-14 | Gutwerg Ori SVP, GENERICS | Shares withheld for taxes | −1,888 | $77.36 | $146K | 76,094 |
| 2026-02-14 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −10,298 | $77.36 | $797K | 358,574 |
Page 4 of 15 · 282 trades